Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by John A. Blessing
Phase II Trial of Nab-Paclitaxel in the Treatment of Recurrent or Persistent Advanced Cervix Cancer: A Gynecologic Oncology Group Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
Related publications
A Phase II Evaluation of Nintedanib (BIBF-1120) in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
Nab-Paclitaxel as Second-Line Treatment in Advanced Gastric Cancer: A Multicenter Phase II Study of the Hellenic Oncology Research Group
Annals of Gastroenterology
Phase II Evaluation of Dasatinib in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
A Phase II Evaluation of Lapatinib in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
A Phase 2 Study of Alisertib (MLN8237) in Recurrent or Persistent Uterine Leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group Study 0231D
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
A Phase II Evaluation of Selumetinib (AZD6244, ARRY-142886), a Selective MEK-1/2 Inhibitor in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
Nab-Paclitaxel: Potential for the Treatment of Advanced Pancreatic Cancer
OncoTargets and Therapy
Oncology
Pharmacology
A Phase I Study of Paclitaxel, Topotecan, Cisplatin and Filgrastim in Patients With Newly Diagnosed Advanced Ovarian Epithelial Malignancies: A Gynecologic Oncology Group Study
Gynecologic Oncology
Gynecology
Oncology
Obstetrics
Radiopharmaceuticals for Persistent or Recurrent Uterine Cervix Cancer
Frontiers in Oncology
Cancer Research
Oncology
